A clinical trial of a subunit vaccine against COVID-19 developed by NIIPBB scientists has been launched

A clinical trial of a subunit vaccine against COVID-19 developed by NIIPBB scientists has been launched

On June 15, 2021, clinical trials of the domestic subunit vaccine against COVID-19 with the involvement of volunteers aged 18 to 50 years began in the multidisciplinary city hospital of Taraz.

The RSE "Research Institute for Biological Safety Problems" of the Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan has received permission from the Ministry of Health of the Republic of Kazakhstan to conduct phase I and II clinical trials of the QazCoVac-P subpublic vaccine based on artificially synthesized proteins of the SARS-CoV – 2 coronavirus, a new vaccine preparation for the prevention of COVID-19.

The named vaccine is the second NIIPBB vaccine that has successfully passed preclinical tests at a specialized enterprise of the Ministry of Health of the Republic of Kazakhstan and has demonstrated its safety.

Thanks to the use of modern molecular biology technologies, the developers were able to obtain strains of bacteria that produce RBD and N proteins, which are recognized by the immune system of the SARS-CoV-2 coronavirus.

To ensure the safety of the vaccine, all stages of complex purification of the obtained proteins were carried out and quality control was carried out. They do not contain a whole virus.

The vaccine promotes the development of immunity in the body of vaccinated laboratory animals on the 14th day after intramuscular administration of the second dose.

As in the composition of inactivated vaccines, subunit vaccines do not contain live components of the pathogen and are absolutely safe.

The adjuvant contained in the vaccine provokes the occurrence of an immune response and does not have a negative effect on the body of the vaccinated person. This is due to the fact that this vaccine contains only the necessary antigens, And all other components of the virus are absent, side effects of the post-vaccination subunit are rare. Examples of this type of vaccine can be vaccines against influenza, hepatitis B, pneumococcus, meningococcus, hemophilus infections, etc.

Successful clinical trials will expand the population of those vaccinated with a subunit vaccine and accelerate the formation of collective immunity to coronavirus in our country.